Skip to main content

News

PALACE 3 Study: Apremilast Shows 52 Wk. Efficacy in Active Psoriatic Arthritis

Apremilast, a novel phosphodiesterase 4 (PDE4) inhibiting conversion of cyclic AMP to AMP, was approved for treatment of psoriatic arthritis (PsA) after showing its efficacy in 16 weeks PALACE 1, 2, and 3 trials in 2014.

10 Ways Rheumatoid Arthritis Could’ve Killed Glenn Frey

I was truly stunned Monday when it was announced that Glenn Frey, from the Eagles, had died as a result of complications from his rheumatoid arthritis, ulcerative colitis and pneumonia.

Methotrexate Nonadherence is Common

Researchers from Belgium studied patient adherence to MTX (given orally or via injection) in 129 rheumatoid arthritis (RA) patients over a 16-week period using an electronic monitoring system and two validated adherence questionnaires.

French Cannibinoid Phase I Study Gone Wrong

Six volunteers were admitted to the University Hospital of Rennes in France last week after partaking in the Phase I trial of a new medication meant to treat mood disorders such as anxiety.

DSB Reports & Updates - January 2016

Comparative Harmful Risks with Targeted Immunomodulators. Desai et al did a systematic review of the literature, findings of 10 head-to-head RCTs and 51 observational studies.

MRI Bone Marrow Lesions Predict Worse Outcomes in Osteoarthritis

Medical Research Council study shows MRI lesions may predict which patients will have more rapidly progressing osteoarthritis. 

FDA Approves Cosentyx for Ankylosing Spondylitis and Psoriatic Arthritis

Cosentyx (secukinumab) was approved by the FDA on 15 January, 2016 for patients with active ankyosing spondylitis (AS) and psoriatic arthritis (PsA).

BSR Issues DMARD Prescribing Guidelines for Pregnancy

Treatment paradigms for managing pregnancy in rheumatoid arthritis (RA) have been challenged in recent years with the introduction of new agents and reclassification of drug safety during pregnancy by the FDA.

Steroid Over-Prescribing Persists in RA

Almost half of patients with rheumatoid arthritis (RA) in the UK receive glucocorticoids from primary care physicians, and of those who are prescribed glucocorticoids, more than half receive more than 10 mg a day.

Ominous Outcomes for Lupus Nephritis

Hanly and coworkers have reported the results of a large lupus cohort study involving 1827 patients. SLE patients were enrolled early in their disease (0.5 years) and were followed for a mean of 4.6 years.

ACP Backs New CDC Guideline for Opioids and Chronic Pain

Wayne J Riley, MD, MPH, MBA, MACP, president of the American College of Physicians (ACP) sent a letter to the Centers for Disease Control and Prevention (CDC) reacting to its Draft Guideline for the Use of Opioids for Chronic Pain.

×